跳到主要导航
跳到搜索
跳到主要内容
Pure University (For Demo Only) 国内
帮助和常见问题
English
中文
国内
简介
研究单位
科研成果
设备
数据集
活动
奖项
影响
项目
新闻 / 媒体
按专业知识、名称或附属进行搜索
联系专家
查看 Scopus 资料
Hall Richard I.
Associate Professor
Dalhousie University
,
Medicine
电子邮件
HR721280
dal
ca
网站
https://www.scopus.com/authid/detail.url?authorId=7404721280
h-index
h10-index
h5-index
9004
引用
44
H-指数
根据存储在 Pure 中的刊物数量以及来自 PlumX 的引用文献数量进行计算
1863
引用
17
H-指数
根据储存在 Pure 的刊物以及来自 Scopus 的引用文献数量计算
193
引用
4
H-指数
根据储存在 Pure 的刊物以及来自 Scopus 的引用文献数量计算
1978 …
2021
每年的科研成果
综述
指纹
网络
科研成果
(160)
新闻 / 媒体
(43)
相似简介
(6)
指纹
深入其中 Hall Richard I. 为活跃的研究主题。这些主题标签来自此人的成果。它们共同形成唯一的指纹。
分类
加权
按字母排序
Medicine and Dentistry
Analgesia
18%
Anemia
10%
Anesthesiologist
21%
Antibiotics
17%
Artificial Respiration
18%
Bleeding
29%
Cardiac Anesthesia
9%
Catecholamine
13%
Clinical Trial
25%
Cohort Analysis
22%
Coronary Artery Bypass Graft Surgery
18%
Coronary Artery Bypass Surgery
11%
Creatine Kinase MB
11%
Critical Illness
12%
Disease
11%
Drug Therapy
15%
Elective Surgery
10%
Electrocardiogram
14%
End of Life Care
17%
Enflurane
25%
Epileptic Absence
12%
Esophagus Motility
9%
Extubation
13%
Fentanyl
9%
Health Care Cost
42%
Heart Muscle Ischemia
14%
Heart Surgery
78%
Heart Ventricle Function
13%
Hemodynamic
35%
Hydrocortisone
10%
Induction of Anesthesia
17%
Infection
10%
Informed Consent
19%
Infusion
11%
Injury
11%
Intensive Care
58%
Intensive Care Unit
100%
Intensivist
13%
Lactic Acid
17%
Midazolam
23%
Myocardial Infarction
18%
Odds Ratio
12%
Propofol
57%
Randomized Controlled Trial
37%
Ranitidine
11%
Sedative Agent
14%
Sufentanil
25%
Thromboembolism
17%
Thromboprophylaxis
30%
Urinary System
11%
Nursing and Health Professions
Antibiotic Therapy
9%
Antimicrobial Therapy
9%
Bacteremia
19%
Biological Marker
9%
Blood-Brain Barrier
9%
Cardiac Anesthesia
9%
Cardioplegia
9%
Cardiopulmonary Bypass
14%
Clinical Effectiveness
9%
Cohort Analysis
16%
Confidence Interval
18%
Coronary Artery Surgery
9%
Cost Effectiveness Analysis
13%
Critical Illness
15%
Dalteparin
16%
Disease
11%
Drug Therapy
23%
Economic Evaluation
23%
End of Life Care
20%
Extubation
14%
Heart Muscle Ischemia
14%
Heart Surgery
34%
Heparin
25%
Heparin Induced Thrombocytopenia
23%
Hospital Infection
9%
Infection
13%
Intensive Care
32%
Intensive Care Unit
86%
Intracranial Pressure
9%
Intraoperative Blood Salvage Device
9%
Low Molecular Weight Heparin
15%
Lung Embolism
13%
Midazolam
14%
Morphine
11%
Odds Ratio
13%
Palliative Therapy
9%
Practice Guideline
12%
Propofol
27%
Prospective Cohort Study
9%
Research Ethics
9%
Sedation
39%
Sedative Agent
16%
Sepsis
9%
Sleep Disordered Breathing
9%
Thoracoabdominal Aorta Aneurysm
9%
Thromboembolism
14%
Treatment Duration
10%
Venous Thromboembolism
11%
Ventilator-Associated Pneumonia
9%
Ward
12%
Keyphrases
Adult Intensive Care
9%
Anemia
10%
Anesthesiologist
9%
Anesthetized Dog
11%
Canada
22%
Canadian Census
9%
Cardiac Surgery
12%
Cardiovascular Anaesthesia
9%
Case-based Review
9%
Cerebral Desaturation
9%
Cerebral Oximetry
9%
Clinical Trials
12%
Clinically Significant
9%
Confidence Interval
16%
Consent Rate
14%
Controlled Randomized Trial
9%
Critically Ill
26%
Critically Ill Patients
58%
Economic Evaluation
12%
Emergency Drugs
9%
Enflurane
29%
Esophageal Motility
9%
Evidence-based Clinical Practice Guideline
9%
Fentanyl
20%
H1N1
9%
Hospital Care
11%
Influenza A (H1N1) Infection
9%
Intensive Care Unit
37%
Investigative Methods
9%
Mechanical Ventilation
17%
Midazolam
22%
Modifiable Risk Factors
9%
Non-associated
12%
Nutrition Intake
9%
Obstructive Sleep Apnea
19%
On-pump Cardiac Surgery
9%
Pharmacokinetics
14%
Prospective Cohort Study
9%
Randomized Controlled Feasibility Trial
9%
Randomized Controlled Trial
16%
Randomized Trial
11%
Regurgitation
9%
S100B
9%
Sedation
19%
Sham Control
9%
Sucralfate
11%
Thrombocytopenia
13%
Thromboprophylaxis
11%
Upper Gastrointestinal Bleeding
14%
Ventilator-associated Pneumonia
13%
